These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 25789503)

  • 1. New therapies for dedifferentiated papillary thyroid cancer.
    Fallahi P; Mazzi V; Vita R; Ferrari SM; Materazzi G; Galleri D; Benvenga S; Miccoli P; Antonelli A
    Int J Mol Sci; 2015 Mar; 16(3):6153-82. PubMed ID: 25789503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
    Cancer Discov; 2016 Oct; 6(10):OF4. PubMed ID: 27554612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
    Isham CR; Netzel BC; Bossou AR; Milosevic D; Cradic KW; Grebe SK; Bible KC
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E936-43. PubMed ID: 24628546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.
    Scott E; Learoyd D; Clifton-Bligh RJ
    Future Oncol; 2016 Nov; 12(22):2603-2613. PubMed ID: 27387641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
    Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
    Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF inhibitors: experience in thyroid cancer and general review of toxicity.
    Cabanillas ME; Patel A; Danysh BP; Dadu R; Kopetz S; Falchook G
    Horm Cancer; 2015 Feb; 6(1):21-36. PubMed ID: 25467940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib therapy in metastatic papillary thyroid cancer.
    Gori S; Foglietta J; Rossi M; Hamzaj A; Stocchi L; Galuppo C; Picece V; Puxeddu E; Furlani L
    Tumori; 2013; 99(6):285e-7e. PubMed ID: 24503805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central role of RET in thyroid cancer.
    Santoro M; Carlomagno F
    Cold Spring Harb Perspect Biol; 2013 Dec; 5(12):a009233. PubMed ID: 24296167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
    Kojic KL; Kojic SL; Wiseman SM
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.